Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference27 articles.
1. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet (London, England). 2007;370(9603):1907–14.
2. Group HTRC, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217–27.
3. Merck Provides Update on Anacetrapib Development Program [Internet]. Available from: https://investors.merck.com/news/press-release-details/2017/Merck-Provides-Update-on-Anacetrapib-Development-Program/default.aspx. Accessed 4 Jul 2019
4. Rashid S. Lower LDL is better—can this be achieved with CETP inhibition therapy? Expert Rev Cardiovasc Ther. 2020;18(1):1–5.
5. Tardif JC, Rheaume E, Lemieux Perreault LP, Gregoire JC, Feroz Zada Y, Asselin G, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8(2):372–82.